Damora Therapeutics (DMRA)
NASDAQ:DMRA
Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$26.60
-$0.21(-3.82%)
At close: 4:00 PM EST
$26.60
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.45 - $38.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.26M
Market Cap
$1.31B
Enterprise Value-$491.81M
Total Cash (Recent Filing)$532.90M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 05, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-172.21
Shares Outstanding61,553,192
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.54
Enterprise Value/Market Cap-0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.23K
Enterprise Value/Ebitda2.15
Forecast
1Y Price Target
$43.14Price Target Upside62.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityNear-zero debt materially reduces solvency and refinancing risk for a pre-revenue biotech. This financial flexibility supports continued R&D and clinical programs without immediate debt pressure, giving management time to reach milestones before needing costly borrowings.
Experienced Leadership And Board OverhaulBringing an industry veteran CEO and experienced directors increases operational and capital-markets credibility. Strengthened governance and management quality improve chances of disciplined clinical development, fundraising execution, and strategic partnerships ahead of key milestones.
Smaller Operating Cash Outflow Trend In 2025A materially reduced cash outflow indicates improved spending discipline or integration savings post-acquisition. This trend extends runway compared with prior year burn, lowering near-term financing urgency and enabling more focused investment on lead program advancement.
Bears Say
No Revenue / Pre-commercial ProfileAbsence of product revenue means the business depends entirely on clinical progress and external financing. Without commercial cash flows, the company faces structural uncertainty on timing of sustainable earnings and remains exposed to trial, regulatory and market execution risks.
Sharply Widening Net Loss In 2025A large, volatile increase in net loss signals heavy one-time or scaling costs and materially inflates funding needs. Persistent large losses erode equity value, increase likelihood of dilution, and constrain strategic optionality until the company demonstrably slows burn or generates revenue.
Negative Cash Generation And Funding DependenceContinued negative operating and free cash flow makes the firm reliant on external capital to fund trials and operations. Ongoing funding needs raise execution risk, may force dilutive financings, and create dependency on capital markets timing regardless of scientific progress.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
Damora Therapeutics lowest stock price was $2.45 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics’s market cap?
Damora Therapeutics’s market cap is $1.31B.
When is Damora Therapeutics’s upcoming earnings report date?
Damora Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 53 days.
How were Damora Therapeutics’s earnings last quarter?
Damora Therapeutics released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.232.
Is Damora Therapeutics overvalued?
According to Wall Street analysts Damora Therapeutics’s price is currently Undervalued.
Does Damora Therapeutics pay dividends?
Damora Therapeutics does not currently pay dividends.
What is Damora Therapeutics’s EPS estimate?
Damora Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Damora Therapeutics have?
Damora Therapeutics has 61,553,192 shares outstanding.
What happened to Damora Therapeutics’s price movement after its last earnings report?
Damora Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went up 4.634%.
Which hedge fund is a major shareholder of Damora Therapeutics?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.14 (62.19% Upside)
$43.14 (62.19% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-122.40%
Trailing 12-Months
Asset Growth
3384.82%
Trailing 12-Months
Company Description
Damora Therapeutics
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
DMRA Stock 12 Month Forecast
Average Price Target
$43.14
▲(62.19% Upside)
Technical Analysis
Ownership Overview
15.99% Insiders
6.66% Mutual Funds
61.80% Other Institutional Investors
14.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---